<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654587</url>
  </required_header>
  <id_info>
    <org_study_id>OSE2101C301</org_study_id>
    <secondary_id>2015-003183-36</secondary_id>
    <nct_id>NCT02654587</nct_id>
  </id_info>
  <brief_title>Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC</brief_title>
  <acronym>ATALANTE 1</acronym>
  <official_title>A Randomized Parallel Group Phase III Trial of OSE 2101 as 2nd Line After Prior Platinum-based Chemotherapy Failure or as 3rd Line After Platinum-failure and Checkpoint Inhibitor-failure, Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OSE Immunotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OSE Immunotherapeutics</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if the Investigational Medicinal Product Tedopi
      (OSE2101) is more effective than standard treatment in treating patients with stage IIIB
      NSCLC unsuitable for radiotherapy or metastatic NSCLC in second- or third-line treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to demonstrate that OSE2101 (Arm A) is superior to standard
      chemotherapy, pemetrexed or docetaxel (Arm B), in prolonging overall survival (OS) in HLA-A2
      positive patients with locally advanced (IIIB) or metastatic NSCLC as 2nd line therapy after
      failure of prior platinum-based chemotherapy or 3rd line after failure of platinum- and
      checkpoint-inhibitor regimens. In Arm B, patients with squamous NSCLC are allocated to
      docetaxel and patients with non-squamous NSCLC are allocated to pemetrexed if they are
      pemetrexed-naive or to docetaxel should they have already received pemetrexed.

      Treatment cycles will be repeated until unequivocal Recist 1.1-defined disease progression
      as determined by the investigator, unacceptable toxicity, or consent withdrawal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Survival time (OS)</measure>
    <time_frame>Approximatively 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Approximatively 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-C30 global score</measure>
    <time_frame>Approximatively 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-LC13 global score</measure>
    <time_frame>Approximatively 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximatively 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes (PRO)</measure>
    <time_frame>Approximatively 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Approximatively 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Approximatively 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Time to deterioration (TTD)</measure>
    <time_frame>Approximatively 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Time to next lung cancer therapy</measure>
    <time_frame>Approximatively 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Type, incidence, severity, seriousness and relationship to study medications of adverse events (AE) and any laboratory abnormalities</measure>
    <time_frame>Approximatively 48 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety and tolerability of OSE2101 compared to pemetrexed or docetaxel</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>OSE2101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSE2101 will be administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every two months for the remainder of year one and finally every three months until unequivocal Recist 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. OSE2101 dose will be 5 mg of peptide (0.5 mg for each peptide).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel or Pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle.
Patients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSE2101</intervention_name>
    <arm_group_label>OSE2101</arm_group_label>
    <other_name>Tedopi</other_name>
    <other_name>EP-2101</other_name>
    <other_name>EP2101</other_name>
    <other_name>IDM-2101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Docetaxel or Pemetrexed</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Docetaxel or Pemetrexed</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent document indicating that the patient (or legally
             acceptable representative) has been informed of all the pertinent aspects of the
             trial prior to enrollment.

          2. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures.

          3. Female or male, 18 years of age or older.

          4. Histologically or cytologically proven diagnosis of NSCLC that is locally advanced
             (stage IIIB) unsuitable for radiotherapy or metastatic (stage IV) according to the
             7th edition of tumor, node, metastasis (TNM) in Lung Cancer published by the
             International Union Against Cancer and the American Joint Committee on Cancer.

          5. Subjects with disease recurrence or progression

               1. Patients must have had progressive disease after only one prior chemotherapy
                  regimen: i) It includes patients who have received one prior platinum-based
                  chemotherapy in the adjuvant setting following surgical resection for early
                  disease and whose disease has recurred within 12 months of completion of prior
                  chemotherapy, ii) It includes patients who received one prior platinum-based
                  chemotherapy in combination with radiation therapy for Stage III locoregional
                  disease and whose disease has recurred within 12 months of completion of prior
                  chemotherapy, iii) It includes patients who received 2 prior platinum-based
                  chemotherapy regimens, if the first regimen was given as adjuvant therapy or was
                  given in combination with radiation therapy for locally advanced disease

               2. or Patients must have had progressive disease after 2nd line therapy with an
                  immune checkpoint inhibitor

          6. Subjects with measurable or non-measurable lesions.

          7. Subjects must express HLA-A2 phenotype as assessed serologically.

          8. Subjects must be considered suitable for chemotherapy with either single-agent
             pemetrexed or docetaxel.

          9. Subjects with brain metastases are eligible if treated and symptoms have returned to
             baseline (except for signs and symptoms related to central nervous system therapy)
             for at least 2 weeks before initiation of allocated treatment and are not taking any
             forbidden medications.

         10. Any prior chemotherapy, immunotherapy, radiation therapy or surgeries must have been
             completed at least 3 weeks prior to initiation of study medication.

         11. Any toxicity from prior therapy must have recovered to ≤ Grade 1 (except alopecia).

         12. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

         13. Adequate organ function as defined by all the following criteria:

               1. Albuminemia &gt; 25g/L

               2. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 1.5 x
                  upper limit of normal (ULN) with alkaline phosphatase ≤ 2.5 x ULN, or AST and
                  ALT ≤ 5 x ULN if liver function abnormalities are due to liver metastases

               3. Total serum bilirubin ≤ 1.5 x ULN

               4. Absolute neutrophil count (ANC) ≥ 1500/L

               5. Platelets ≥ 100000/L

               6. Hemoglobin ≥ 9.0 g/dL (in the absence of transfusion within 2 weeks before
                  randomization)

               7. Creatinine clearance (based on modified Cockcroft-Gault formula) ≥ 45 ml/min.

        Exclusion Criteria:

          1. Small-cell lung cancer/mixed NSCLC with small cell component or other neuroendocrine
             lung cancers (typical and atypical carcinoids, large-cell neuroendocrine carcinomas).
             Large-cell carcinoma.

          2. NSCLC that is predominantly squamous cell carcinoma, and patient had docetaxel as
             part of his prior chemotherapy.

          3. Current or previous treatment with investigational therapy in another therapeutic
             clinical trial interrupted less than 4 weeks before study treatment initiation.

          4. Patients whose tumor harbors EGFR gene mutation that sensitizes tumors to
             Tyrosine-Kinase Inhibitor (TKI) (EGFR exon 18-21) or Anaplastic Lymphoma Kinase (ALK)
             rearrangement.

          5. Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy).

          6. Spinal cord compression (unless treated with the patient attaining good pain control
             and stable or recovered neurologic function), carcinomatous meningitis, or
             leptomeningeal disease

          7. Patients with squamous cell histology or non-squamous cell histology previously
             treated by pemetrexed and with a contraindication for docetaxel with grade ≥ 2
             neuropathy or hypersensitivity reaction to medications formulated with polysorbate
             80) as they could be randomly assigned to Arm B.

          8. Patients with a condition requiring systemic treatment with either corticosteroids or
             other immunosuppressive medications.

          9. Treatment with corticosteroids in the last 3-week period before inclusion, except for
             topical, ocular, intra-articular, intranasal, and inhaled corticosteroids with
             minimal systemic absorption (e.g. with a dose ≤ 500 microgram beclomethasone
             equivalent for inhaled steroids), or adrenal replacement steroid doses ≤ 10 mg daily
             prednisone equivalent which are permitted.

         10. A recognized immunodeficiency disease including human immunodeficiency virus (HIV)
             infection (and other cellular immunodeficiencies, hypogammaglobulinemia or
             dysgammaglobulinemia; subjects who have hereditary, congenital or acquired
             immunodeficiencies).

         11. Patients with auto-immune disease, with the exception of type I diabetes or treated
             hypothyroidism.

         12. Patients with interstitial lung disease.

         13. Patients with active B or C hepatitis.

         14. Other malignancy: patients will not be eligible if they have evidence of active
             malignancy (other than non-melanoma skin cancer or localized cervical cancer, or
             localized and presumed cured prostate cancer).

         15. Other severe acute or chronic medical or psychiatric conditions, or laboratory
             abnormalities that would impart, in the judgment of the investigator and/or sponsor,
             excess risk associated with study participation or study drug administration, and
             which would, therefore, make the patient inappropriate for entry into this study.

         16. Female patients must be surgically sterile or be postmenopausal, or must agree to use
             effective contraception during the period of the trial and for at least 90 days after
             completion of treatment.

         17. Male patients sexually active with a woman of childbearing potential must be
             surgically sterile or must agree to use effective contraception during the period of
             the trial and for at least 90 days after completion of treatment. The decision of
             effective contraception will be based on the judgment of the principal investigator.

         18. Breastfeeding women.

         19. Women with a positive pregnancy test.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alain Chatelin, MD</last_name>
    <email>alain.chatelin@ose-immuno.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Timothy R Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giuseppe Giaconne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic LLP</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christopher Miles McCanless, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center at West Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Chester</last_name>
      <phone>504-349-6019</phone>
      <email>maria.chester@wjmc.org</email>
    </contact>
    <investigator>
      <last_name>Scott Sonnier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center Hematology and Oncology</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marthe Thomas</last_name>
      <phone>662-377-4550</phone>
      <email>mmthomas@nmhs.net</email>
    </contact>
    <investigator>
      <last_name>Andrew H Kellum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridian Health</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jatin K Desani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>208</phone_ext>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingrid Block</last_name>
      <phone>405-271-8777</phone>
      <email>Ingrid-Block@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammad Razaq, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Designer Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rajiv Panikker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Satih Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Cancer Center - Georgetown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Benjamin Joel Downie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Jordan</last_name>
      <phone>972-566-3000</phone>
      <email>referral@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>John Nemunaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Millenium Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anirudha Dasgupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava, Onkologické oddelení</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lubomír Slavícek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krajská nemocnice Liberec</name>
      <address>
        <city>Liberec</city>
        <zip>46063</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marek Sochor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut onkologie a rehabilitace Na Pleši</name>
      <address>
        <city>Nová Ves pod Pleší</city>
        <zip>26204</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Petra Garnolová, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika tuberkulózy a respiracních nemocí, FNO</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaromír Roubec, MD</last_name>
      <phone>+420 597 372 240</phone>
      <email>jaromir.roubec@fno.cz</email>
    </contact>
    <contact_backup>
      <last_name>Jaromír Roubec, MD</last_name>
      <phone>+420 597 374 232</phone>
    </contact_backup>
    <investigator>
      <last_name>Jaromír Roubec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pardubická krajská nemocnice</name>
      <address>
        <city>Pardubice</city>
        <zip>53203</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Iveta Kolárová/Vanasek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Všeobecná Fakultní nemocnice</name>
      <address>
        <city>Praha</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Milada Zemanova, Doc,MUDr,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masarykova nemocnice v Usti nad Labem</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pavel Reiterer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LeMoulec, MD</last_name>
      <phone>+33 5 56 33 32 22</phone>
    </contact>
    <investigator>
      <last_name>LeMoulec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Girard, MD</last_name>
      <phone>+33 4 72 35 76 52</phone>
    </contact>
    <contact_backup>
      <last_name>Raphaële Guelminger</last_name>
      <phone>+33 4 72 35 70 74</phone>
    </contact_backup>
    <investigator>
      <last_name>Nicolas Girard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos Chouaid, MD</last_name>
      <phone>+33 1 57 02 20 70</phone>
      <email>christos.chouaid@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Christos Chouaid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Réda Chebel</last_name>
      <phone>+33 2 43 43 27 64</phone>
      <email>rchebel@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Molinier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Debieuvre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Pouessel, MD</last_name>
      <phone>+33 1 42 49 42 47</phone>
      <email>damien.pouessel@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Damien Pouessel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Prigent</last_name>
      <phone>+33 2 99 28 97 95</phone>
      <email>melanie.prigent@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Romain Corre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elisabeth Quoix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey - CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Amigues</last_name>
      <phone>+33 5 67 77 17 58</phone>
      <email>amigues.s@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Julien Mazières, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Rayez</last_name>
      <phone>+33 2 47 47 47 47</phone>
      <email>m.rayez@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Pichon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy (IGR)</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Kahn Charpy</last_name>
      <phone>+33 142 114 211</phone>
      <email>virginie.kahn-charpy@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Benjamin Besse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont II szamu telephely</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Júlia Lászlóné Petőcz</last_name>
      <phone>+36 22 535 722</phone>
      <email>jplaszlone@mail.fmkorhaz.hu</email>
    </contact>
    <investigator>
      <last_name>Zsuzsanna Papai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrienn Heisz</last_name>
      <phone>+36 20 966 2944</phone>
      <email>Adrienn.Heisz@coordination.hu</email>
    </contact>
    <investigator>
      <last_name>Lajos Geczi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Altalanos Orvostudományi Kar Pulmonologiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zoltán Hajzer</last_name>
      <phone>+36 20 430 1176</phone>
      <email>zoltan.hajzer@coordination.hu</email>
    </contact>
    <investigator>
      <last_name>György Losonczy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Csongrad Megyei Mellkasi Betegsegek Szakkorháza I Tüdőosztály</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rózsa Lászlóné Kovács</last_name>
      <phone>+36 62 571 552</phone>
      <email>office.tudtsz@med.u-szeged.hu</email>
    </contact>
    <investigator>
      <last_name>Attila Somfay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Borsod Abauj Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz Klinikai Onkologiai és Sugarterapiás Osztaly</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Szilvia Ligay</last_name>
      <phone>+36 30 269 0389</phone>
      <email>coordinator@bazmkorhaz.hu</email>
    </contact>
    <investigator>
      <last_name>János Revesz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Matrai Gyogyintézet</name>
      <address>
        <city>Mátraháza</city>
        <zip>3233</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>István Albert, MD</last_name>
      <phone>+36 20 270 8215</phone>
      <email>dr.albert@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>István Albert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gábor Kozma</last_name>
      <phone>+36 20 444 6039</phone>
      <email>kozmagabor989@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Zsolt Papai-Szekely, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gruppo Interdisciplinare Veronese Oncologia Polmonare - AOUI</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Galetta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedal San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alberto Sobrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Oncologia dell'Ospedale Vito Fazzi di Lecce, Piazza Muratore</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giampero Romano, MD</last_name>
      <phone>+39 8 32 66 19 62</phone>
    </contact>
    <investigator>
      <last_name>Giampero Romano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Pneumologia a indirizzo oncologico, Presidio Ospedaliero Monaldi - Azienda Ospedaliera dei Colli - Via Leonardo Bianchi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>antonio Rea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria pisana Pneumologia 2</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Chella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Santa Maria alle Scotte</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Maria Giacomo</last_name>
      <phone>+39 5 77 58 63 05</phone>
      <email>a.m.digiacomo@ao-siena.toscana.it</email>
    </contact>
    <contact_backup>
      <last_name>Elisa Ibba</last_name>
      <phone>+39 5 77 58 63 26</phone>
      <email>ibbaelisa24@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Maio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, Nemunaitis J, Ishioka G, Pappen B, Nemunaitis M, Morse M, Mills B, Maples PB, Sherman J, Nemunaitis JJ. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25. doi: 10.1200/JCO.2008.16.6462.</citation>
    <PMID>18802154</PMID>
  </reference>
  <reference>
    <citation>Beebe M, Qin M, Moi M, Wu S, Heiati H, Walker L, Newman M, Fikes J, Ishioka GY. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy. Hum Vaccin. 2008 May-Jun;4(3):210-8. Epub 2010 May 11.</citation>
    <PMID>18382135</PMID>
  </reference>
  <reference>
    <citation>Nemunaitis J, Cunningham, C ,Bender, J, Ishioka, G, Maples, P, Pappen, B, Stephenson, J, Morse, M, Mills, B, Greco, A, McCune, D, Steis, R, Nugent, F, Khong, HT, Richards, D. Phase II trial of a 10-epitope CTL vaccine, IDM-2101, in metastatic NSCLC patients: Induction of immune responses and clinical efficacy. International Society for Biological Therapy of Cancer 2007, p 891-2.</citation>
  </reference>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 3, 2016</lastchanged_date>
  <firstreceived_date>January 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small-Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cancer vaccine</keyword>
  <keyword>Metastasis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
